FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1924364933> ?p ?o ?g. }

• W1924364933 endingPage "1044" @default.
• W1924364933 startingPage "1036" @default.
• W1924364933 abstract "ABSTRACT Purpose In recent years, the number of oral anticancer agents has increased substantially. Although these agents have quickly been incorporated in the treatment of a variety of malignancies, data on their incidence, prevalence and costs are lacking. The objective of the present study was to obtain insight into the use and the costs of oral anticancer agents (with Anatomical Therapeutic Chemical classification system (World Health Organisation) code L01) in the Netherlands between 2000 and 2008. Methods Incidence and prevalence were determined using community pharmacy dispensing records obtained from the PHARMO Record Linkage System database. The data of costs were provided by the Genees‐ en hulpmiddelen Informatie Project of the Dutch Health Care Insurance Board (CVZ, Diemen, The Netherlands). Results In the years 2000–2008, the use of oral anticancer agents has more than doubled from 64 to 140 users per 100 000 inhabitants. The increase is mainly caused by the prescription of capecitabine for various indications. There was a 50‐fold rise in costs on oral anticancer agents from €2 m in 2000 to approximately €100 m in 2008. The share in the costs of tyrosine kinase inhibitors (TKIs) in 2008 was 67% (€70 m) with the oldest TKI, imatinib, having a share of more than 50% within the group of TKIs. Conclusions The increased use of oral anticancer agents is mainly due to the frequent prescription of capecitabine. The increased costs are caused by the registration of a variety of TKIs, in particular imatinib. The costs of new agents with an orphan drug status are very high as compared with those of capecitabine, a newer agent for which there are alternative treatment options. Copyright © 2011 John Wiley & Sons, Ltd." @default.
• W1924364933 created "2016-06-24" @default.
• W1924364933 creator A5000171890 @default.
• W1924364933 creator A5041640238 @default.
• W1924364933 creator A5052136026 @default.
• W1924364933 creator A5070488540 @default.
• W1924364933 creator A5088663155 @default.
• W1924364933 date "2011-09-29" @default.
• W1924364933 modified "2023-09-26" @default.
• W1924364933 title "Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008" @default.
• W1924364933 cites W1976244025 @default.
• W1924364933 cites W1985807041 @default.
• W1924364933 cites W1994193851 @default.
• W1924364933 cites W1999333578 @default.
• W1924364933 cites W2005850646 @default.
• W1924364933 cites W2010938751 @default.
• W1924364933 cites W2016833582 @default.
• W1924364933 cites W2031077231 @default.
• W1924364933 cites W2050083434 @default.
• W1924364933 cites W2052055688 @default.
• W1924364933 cites W2066604995 @default.
• W1924364933 cites W2073245686 @default.
• W1924364933 cites W2096287682 @default.
• W1924364933 cites W2099088585 @default.
• W1924364933 cites W2105100844 @default.
• W1924364933 cites W2105765694 @default.
• W1924364933 cites W2107268345 @default.
• W1924364933 cites W2112602910 @default.
• W1924364933 cites W2114780052 @default.
• W1924364933 cites W2115901621 @default.
• W1924364933 cites W2119900897 @default.
• W1924364933 cites W2122191640 @default.
• W1924364933 cites W2127631797 @default.
• W1924364933 cites W2139083181 @default.
• W1924364933 cites W2139511378 @default.
• W1924364933 cites W2157824687 @default.
• W1924364933 cites W2158233910 @default.
• W1924364933 cites W2158681922 @default.
• W1924364933 cites W2165863996 @default.
• W1924364933 cites W2215269061 @default.
• W1924364933 cites W4211019965 @default.
• W1924364933 cites W4211135634 @default.
• W1924364933 cites W4244626580 @default.
• W1924364933 doi "https://doi.org/10.1002/pds.2225" @default.
• W1924364933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21956857" @default.
• W1924364933 hasPublicationYear "2011" @default.
• W1924364933 type Work @default.
• W1924364933 sameAs 1924364933 @default.
• W1924364933 citedByCount "16" @default.
• W1924364933 countsByYear W19243649332012 @default.
• W1924364933 countsByYear W19243649332013 @default.
• W1924364933 countsByYear W19243649332014 @default.
• W1924364933 countsByYear W19243649332017 @default.
• W1924364933 countsByYear W19243649332018 @default.
• W1924364933 countsByYear W19243649332019 @default.
• W1924364933 countsByYear W19243649332020 @default.
• W1924364933 countsByYear W19243649332021 @default.
• W1924364933 crossrefType "journal-article" @default.
• W1924364933 hasAuthorship W1924364933A5000171890 @default.
• W1924364933 hasAuthorship W1924364933A5041640238 @default.
• W1924364933 hasAuthorship W1924364933A5052136026 @default.
• W1924364933 hasAuthorship W1924364933A5070488540 @default.
• W1924364933 hasAuthorship W1924364933A5088663155 @default.
• W1924364933 hasConcept C100406419 @default.
• W1924364933 hasConcept C104863432 @default.
• W1924364933 hasConcept C120665830 @default.
• W1924364933 hasConcept C121332964 @default.
• W1924364933 hasConcept C121608353 @default.
• W1924364933 hasConcept C126322002 @default.
• W1924364933 hasConcept C23276603 @default.
• W1924364933 hasConcept C2426938 @default.
• W1924364933 hasConcept C2776865356 @default.
• W1924364933 hasConcept C2777583451 @default.
• W1924364933 hasConcept C2777909004 @default.
• W1924364933 hasConcept C2778729363 @default.
• W1924364933 hasConcept C3019892230 @default.
• W1924364933 hasConcept C512399662 @default.
• W1924364933 hasConcept C526805850 @default.
• W1924364933 hasConcept C61511704 @default.
• W1924364933 hasConcept C71924100 @default.
• W1924364933 hasConcept C98274493 @default.
• W1924364933 hasConceptScore W1924364933C100406419 @default.
• W1924364933 hasConceptScore W1924364933C104863432 @default.
• W1924364933 hasConceptScore W1924364933C120665830 @default.
• W1924364933 hasConceptScore W1924364933C121332964 @default.
• W1924364933 hasConceptScore W1924364933C121608353 @default.
• W1924364933 hasConceptScore W1924364933C126322002 @default.
• W1924364933 hasConceptScore W1924364933C23276603 @default.
• W1924364933 hasConceptScore W1924364933C2426938 @default.
• W1924364933 hasConceptScore W1924364933C2776865356 @default.
• W1924364933 hasConceptScore W1924364933C2777583451 @default.
• W1924364933 hasConceptScore W1924364933C2777909004 @default.
• W1924364933 hasConceptScore W1924364933C2778729363 @default.
• W1924364933 hasConceptScore W1924364933C3019892230 @default.
• W1924364933 hasConceptScore W1924364933C512399662 @default.
• W1924364933 hasConceptScore W1924364933C526805850 @default.
• W1924364933 hasConceptScore W1924364933C61511704 @default.
• W1924364933 hasConceptScore W1924364933C71924100 @default.

• next